Revenue segments as reported by the company.

Technology & Analytics Solutions

Research & Development Solutions

Contract Sales & Medical Solutions

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Depreciation and amortization

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IQVIA Hlds

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IQVIA reports solid Q4 performance, addresses macro challenges proactively

IQVIA delivered a strong performance in Q4 2022 with revenue growth, operational achievements, and solid financial guidance for 2023, underlining its market position and strategic focus.
While facing challenges from macroeconomic factors, wage inflation, and market conditions, the company is proactively addressing these issues through cost-cutting measures and debt reduction strategies.
By leveraging its strengths in stable operations, record bookings, and financial discipline, IQVIA aims to navigate challenges, capitalize on opportunities, and drive sustainable growth in the future.

IQVIA reports solid Q1 growth amidst industry challenges and opportunities

IQVIA Hlds (IQV) Q1 2023 reflects strong financial performance and operational resilience.
Challenges in backlog burn and industry dynamics are being managed effectively.
Opportunities in M&A activity and demand for real-world evidence drive growth.
Steady guidance for 2023 positions the company well for future success.

IQVIA posts strong Q2 results, eyes growth amid AI investments

IQVIA's Q2 performance reflects solid growth and strategic wins in data and analytics solutions.
While facing challenges in decision delays and economic uncertainties, the company's AI investments and strong R&DS segment offer growth opportunities.
With a focus on leveraging AI across business areas and a vast patient data advantage, IQVIA is well-positioned for future success.

IQVIA reports mixed Q3 results, eyes growth through strategic initiatives

IQVIA's Q3 2023 performance showcased strength in R&DS bookings and revenue growth, while TAS faced challenges from foreign exchange and weak demand. The company aims to drive growth through new contracts, cost reduction initiatives, and strategic pricing adjustments, with a focus on stabilizing performance and pursuing growth opportunities in 2024.

IQVIA reports robust Q4 earnings, eyes growth amid challenges

IQVIA's strong performance in bookings and revenue growth positions it well for future success.
While facing challenges in TAS and pricing negotiations, IQVIA's contract wins and guidance for 2024 show resilience.
Opportunities lie in improving demand for TAS, increasing RFPs, and growth in the data business.
Overall, IQVIA's strategic wins and financial outlook indicate a positive trajectory for the company.

IQVIA reports solid Q1 performance, eyes growth through partnerships

IQVIA delivered a solid performance in Q1 2024, meeting revenue expectations and showcasing growth in bookings and pipeline. The company's strengths lie in technology-enabled solutions, global partnerships, and public health initiatives.
Challenges include cancellations impacting revenue, pricing pressures, and the need to navigate market dynamics. However, IQVIA's opportunities in innovation, partnerships, and market expansion position it well for future growth.
Overall, IQVIA's strategic focus on technology, client engagements, and public health initiatives, amidst challenges in cancellations and pricing pressures, presents a resilient outlook. The company's financial performance and industry leadership are key strengths.
With a proactive approach to challenges and a focus on seizing opportunities, IQVIA remains well-positioned for sustained growth and success in the evolving healthcare landscape. The company's adaptability and strategic initiatives drive confidence in its future prospects.

IQVIA reports robust Q2 earnings, eyes growth amidst market challenges

IQVIA Hlds delivered a strong Q2 performance with revenue and earnings growth, supported by efficient operations and solid financial metrics.
While facing challenges such as pricing pressures and market dynamics, the company remains optimistic about future opportunities and growth potential.
Strategic focus on addressing challenges and seizing opportunities will be key to sustaining performance and maximizing shareholder value in the dynamic healthcare landscape.

IQVIA Hlds reports Q3 growth, faces study delays and pricing challenges

IQVIA Hlds demonstrated solid financial performance in Q3 2024, driven by revenue growth and increased EPS.
While facing challenges like study delays and pricing pressures, the company's strategic strengths and opportunities for growth remain intact.
With a focus on share buybacks and R&DS growth, IQVIA is positioning itself for sustained success in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity

IQVIA's Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Global spending on medicines — using invoice price levels — is expected to grow at 3-6 percent CAGR through 2025 to reach about $1.6 trillion by 2025, excluding spending of COVID-19 vaccines, according to a new research report The Global Spending and Usage of Medicines released by the IQVIA™ Institute for Human Data Science. The total cumulative spending on COVID-19 vaccines through 2025 is projected to be $157 billion, largely focused on the initi

Global Medicine Spending to Reach $1.6 Trillion in 2025 Excluding Spending on COVID-19 Vaccines, According to IQVIA Institute for Human Data Science Study

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced Connected Intelligence™, its innovative approach to enabling life sciences customers to discover powerful new insights, drive smarter decision-making, and get treatments to patients faster. Connected Intelligence brings together IQVIA's unique portfolio of capabilities to create inte

IQVIA Announces Connected Intelligence™

IQVIA (IQV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

IQVIA (IQV) Hits Fresh High: Is There Still Room to Run?

Iqvia Holdings saw an improvement in its IBD SmartSelect Composite Rating Friday, from 92 to 98. The post Stocks With Rising Composite Ratings: qvia Holdings appeared first on Investor's Business Daily.

Stocks With Rising Composite Ratings: Iqvia Holdings

IQVIA Holdings Inc. (IQV) CEO Ari Bousbib on Q1 2021 Results - Earnings Call Transcript

IQVIA's (IQV) first-quarter 2021 earnings and revenues increase year over year.

IQVIA (IQV) Beats on Q1 Earnings & Revenues, Raises 2021 View

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA revenue for the first quarter of $3,409 million increased 23.8 percent on a reported basis and 21.4 percent at constant currency

IQVIA Reports First-Quarter Results; Raises Full-Year 2021 Guidance

IQVIA's (IQV) first-quarter 2021 earnings and revenues are expected to have improved year over year.

What's in Store for IQVIA Holdings (IQV) in Q1 Earnings?

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2021 financial results before the market opens on Thursday, April 22, 2021. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slid

IQVIA to Announce First-Quarter 2021 Results on April 22, 2021

IQVIA (IQV) Hits 52-Week High, Can the Run Continue?

The latest deal is expected to help IQVIA (IQV) strengthen its Research & Development Solutions segment.

IQVIA (IQV) Buys Remaining Q2 Solutions Stake, Ups EPS View

Quest Diagnostics

SECAUCUS, N.J. and RESEARCH TRIANGLE PARK, N.C.

Quest Diagnostics Sells Ownership Interest in Q² Solutions to IQVIA

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the acquisition of the 40 percent minority share of Q2 Solutions from Quest Diagnostics (NYSE: DGX), the world leader in diagnostic information services, for $760 million, resulting in 100 percent ownership by IQVIA. The transaction has been fi

IQVIA Acquires Remaining Interest in Q2 Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?

Why Is IQVIA (IQV) Down 1.8% Since Last Earnings Report?

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) announced today that more than 60 trials spanning over 40 countries utilize its innovative decentralized clinical trial solutions as part of their respective registration trials. Many of these trials, launched in 2020 as virtual and patient-centric solutions, are providing business continuity measures to sponsors during the global pandemic. This milestone reflects the growing need for flexibility in clinical resea

IQVIA Virtual Trial Solutions Used in More than 60 Trials

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--IQVIA™ (NYSE: IQV) announces that since September 2020 it has been collaborating with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, on the Phase 3 COVID-19 vaccine clinical trials. The studies leverage IQVIA's suite of decentralized trial solutions that support both on-site and remote study delivery through a mix of telehealth technologies, virtual oversight, and digit

IQVIA Collaborating with Janssen Research & Development on Their Investigational COVID-19 Vaccine Trials

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on Tuesday, March 09, 2021 at 3:00 p.m. EST. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast also will be available

IQVIA to Participate in the Barclays Global Healthcare Conference on March 09, 2021

IQVIA (IQV) has a strong healthcare-specific global IT infrastructure, analytics-driven clinical development capabilities and a robust real-world solutions ecosystem.

IQVIA (IQV) Rides on Life Sciences Strength, Debt Woes Stay

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €1,450,000,000 in aggregate principal amount of senior notes, consisting of €550,000,000 in aggregate principal amount of senior notes due 2026 (the “2026 Notes”) and €900,000,000 in aggregate principal amount of senior notes due 2029 (the “2029 Notes” and, together with the 2026 Notes, the “No

IQVIA Announces Pricing of Offering of Senior Notes

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) today announced that 140 life science companies in nearly 90 countries have selected Orchestrated Customer Engagement (OCE) as their customer engagement solution. This milestone reflects the growing demand within the market for IQVIA's commercial technology to meet the evolving needs of life science companies. Most recently, Laboratoires Théa, a leading independent eye care group in Europe, has joined the growing l

IQVIA's Orchestrated Customer Engagement (OCE) Solution Selected by 140 Life Sciences Companies in Nearly 90 Countries

IQVIA Holdings Inc.'s (IQV) CEO Ari Bousbib on Q4 2020 Results - Earnings Call Transcript

IQVIA's (IQV) fourth-quarter 2020 revenues and earnings increase year over year.

IQVIA (IQV) Beats on Q4 Earnings & Revenues, Raises 2021 View

IQVIA (IQV) delivered earnings and revenue surprises of 4.98% and 4.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

IQVIA Holdings (IQV) Q4 Earnings and Revenues Beat Estimates

IQVIA's (IQV) fourth-quarter 2020 earnings and revenues are expected to have improved year over year.

News for IQVIA Hlds Stock (IQV)